Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)The Johns Hopkins University, School of Medicine Baltimore, Maryland 21205-2196 E-Mail: adhess@jhmi.edu Systemic'chemotherapy including high dose chemotherapy with stem cell rescue frequently induces responses in women with metastatic breast cancer. Unfortunately, disease often recurs due to the persistence of chemotherapy resistant tumor cells. The immune system can effectively target and kill chemotherapy resistant tumor cells. Tumor associated antigens particularly antigens derived from the Her-2/neu oncogene can be recognized in breast cancer. Strategies to enhance immune recognition of these antigens may provide a therapeutic benefit. Recent studies indicate that the N-terminal flanking region of the invariant chain peptide termed CLIP has superagonisitc properties. The central hypothesis of this research project is that the N-terminal flanking region of CLIP can augment the immunogenicity of cryptic "self peptide epitopes from Her-2/neu. Ongoing studies indicate that immunization with chimeric constructs of an MHC class II binding peptide antigen from Her-2/neu presented on tumor cells or on dendritic cells in concert with an MHC class I binding peptide from Her-2/neu induces a potent cytolytic T cell response and protective antitumor immunity. Further analysis of the cell-mediated immune mechanisms reveals that immunization with the chimeric Her-2/neu construct triggers a type 1 cytokine (IL-2, IFNy) T helper cell response. The type 1 cytokine response may underlie the induction of protective antitumor immunity allowing for the clonal amplification of effector T cells and inducing upregulation of target antigens on the tumor cell. Importantly, immunization with the chimeric construct appears to enhance antitumor immunity even in the presence of growing tumors. Augmenting the immune response to tumor associated antigens will enhance therapeutic strategies for the treatment of breast cancer.
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)U14. Subject Terms (keywords previously assigned to proposal abstract or terms which apply to this award)